IP Library › Granted Patent US 12,187,752
Granted Patent B2
US 12,187,752 · App. 18/476,050 · Granted Jan 7, 2025

Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof

Inventors: Christopher J. Burns (Malvern, PA); Daniel C. Pevear (Downingtown, PA); Luigi Xerri (Wayne, PA); Timothy Henkel (Berwyn, PA); Daniel McGarry (Malvern, PA); Lawrence Rosen (Malvern, PA); Gerald Brenner (Plymouth, PA); Jean-Baptiste Arlin (Amsterdam, NL); Ana Fernandez Casares (Amsterdam, NL)
Assignee: VENATORX PHARMACEUTICALS, INC.
C07F5/027A61K9/0095A61K47/02A61K47/12A61K47/183A61K47/26A61P31/04A61K9/0019A61K31/546
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,187,752
App. No.
18/476,050
Granted
Jan 7, 2025
Kind
B2
Abstract

Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for treating a subject in need thereof with a bacterial infection.

Claims (19)

1. A pharmaceutical composition comprising:

(i) (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl) acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid:

or a pharmaceutically acceptable salt, a solvate, or a pharmaceutically acceptable salt and solvate thereof;

(ii) cefepime; and

(iii) L-arginine.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated as a homogeneous liquid suitable for injection.

3. The pharmaceutical composition of claim 2 , further comprising an aqueous carrier.

4. The pharmaceutical composition of claim 3 , wherein the aqueous carrier is water for injection, 0.9% sodium chloride injection, 5% dextrose injection, 10% dextrose injection, sodium lactate injection, 5% dextrose and 0.9% sodium chloride injection, lactated Ringers and 5% dextrose injection, sodium chloride/sodium acetate/sodium gluconate/potassium chloride/magnesium chloride injection, sodium chloride/potassium acetate/magnesium acetate in 5% dextrose injection, or any combinations thereof.

5. The pharmaceutical composition of claim 2 having a pH from about 4 to about 9.

6. The pharmaceutical composition of claim 2 having a pH from about 4 to about 6.

7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated as a powder for reconstitution.

8. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is suitable for injection once reconstituted with an aqueous carrier.

9. The pharmaceutical composition of claim 8 , wherein the aqueous carrier is water for injection, 0.9% sodium chloride injection, 5% dextrose injection, 10% dextrose injection, sodium lactate injection, 5% dextrose and 0.9% sodium chloride injection, lactated Ringers and 5% dextrose injection, sodium chloride/sodium acetate/sodium gluconate/potassium chloride/magnesium chloride injection, sodium chloride/potassium acetate/magnesium acetate in 5% dextrose injection, or any combinations thereof.

10. The pharmaceutical composition of claim 1 , wherein (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl) acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid or a pharmaceutically acceptable salt, a solvate, or a pharmaceutically acceptable salt and solvate thereof is (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl) acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid dihydrochloride.

11. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises about 500 mg of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl) acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid, a pharmaceutically acceptable salt, a solvate, or a pharmaceutically acceptable salt and solvate thereof.

12. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises about 750 mg of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl) acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid, a pharmaceutically acceptable salt, a solvate, or a pharmaceutically acceptable salt and solvate thereof.

13. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises about 2 g of cefepime.

14. A method of treating a bacterial infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of claim 1 .

15. The method of claim 14 , wherein the pharmaceutical composition is administered by intravenous (IV) infusion.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2023
From: BRENNER, GERALD
To: VENATORX PHARMACEUTICALS, INC.
Reel/Frame 065873/0585 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2023
From: ARLIN, JEAN-BAPTISTE; FERNANDEZ CASARES, ANA
To: CRYSTALLICS B.V.
Reel/Frame 065873/0588 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2023
From: CRYSTALLICS B.V.
To: VENATORX PHARMACEUTICALS, INC.
Reel/Frame 065873/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2023
From: BURNS, CHRISTOPHER J.; PEVEAR, DANIEL C.; XERRI, LUIGI; HENKEL, TIMOTHY; MCGARRY, DANIEL; ROSEN, LAWRENCE
To: VENATORX PHARMACEUTICALS, INC.
Reel/Frame 065873/0606 →
Continuity (7)
Continuation 17353377 · Jun 21, 2021
Division 16491116
Provisional Application 62564989 · Sep 28, 2017
Provisional Application 62564990 · Sep 28, 2017
Provisional Application 62467752 · Mar 6, 2017
Provisional Application 62467750 · Mar 6, 2017
Related Publication 20240101580A1 · Mar 28, 2024
References Cited (106)
US 7271186B1 · Shoichet et al. · 2007 [cited by applicant]
US 7714159B2 · Pickersgill et al. · 2010 [cited by applicant]
US 8283467B2 · Ammoscato et al. · 2012 [cited by applicant]
US 8912169B2 · Burns et al. · 2014 [cited by applicant]
US 9040504B2 · Burns et al. · 2015 [cited by applicant]
US 9376454B2 · Burns et al. · 2016 [cited by applicant]
US 9403850B2 · Burns et al. · 2016 [cited by applicant]
US 9422314B2 · Burns et al. · 2016 [cited by applicant]
US 9637504B2 · Burns et al. · 2017 [cited by applicant]
US 9771382B2 · Burns et al. · 2017 [cited by applicant]
US 9828391B2 · Burns et al. · 2017 [cited by applicant]
US 10214547B2 · Burns et al. · 2019 [cited by applicant]
US 10669290B2 · Burns et al. · 2020 [cited by applicant]
US 10889600B2 · Amann et al. · 2021 [cited by applicant]
US 11091505B2 · Burns et al. · 2021 [cited by applicant]
US 11560392B2 · Amann et al. · 2023 [cited by applicant]
US 11820784B2 · Burns et al. · 2023 [cited by applicant]
US 20090156518A1 · Zhang · 2009 [cited by applicant]
US 20100120715A1 · Burns et al. · 2010 [cited by applicant]
US 20100286092A1 · Burns et al. · 2010 [cited by applicant]
US 20100292185A1 · Burns et al. · 2010 [cited by applicant]
US 20100317621A1 · Burns et al. · 2010 [cited by applicant]
US 20110294777A1 · Blizzard et al. · 2011 [cited by applicant]
US 20120040932A1 · Hirst et al. · 2012 [cited by applicant]
US 20140171390A1 · Burns · 2014 [cited by examiner]
US 20140194385A1 · Reddy et al. · 2014 [cited by applicant]
US 20140194386A1 · Burns et al. · 2014 [cited by applicant]
US 20150094472A1 · Hecker et al. · 2015 [cited by applicant]
US 20150361107A1 · Trout · 2015 [cited by applicant]
US 20170073360A1 · Burns et al. · 2017 [cited by applicant]
US 20170281639A1 · Kawasaki et al. · 2017 [cited by applicant]
US 20180002351A1 · Hecker et al. · 2018 [cited by applicant]
US 20220054513A1 · Hamrick et al. · 2022 [cited by applicant]
CN 1965838A · 2007 [cited by applicant]
CN 105801610A · 2016 [cited by applicant]
JP 2015508801A · 2015 [cited by applicant]
KR 20130064004A · 2013 [cited by applicant]
RU 2445314C9 · 2013 [cited by applicant]
WO WO2005097809A2 · 2005 [cited by applicant]
WO WO2009064413A1 · 2009 [cited by applicant]
WO WO2009064414A1 · 2009 [cited by applicant]
WO WO2010056827A1 · 2010 [cited by applicant]
WO WO2010130708A1 · 2010 [cited by applicant]
WO WO2012021455A1 · 2012 [cited by applicant]
WO WO2013014497A1 · 2013 [cited by applicant]
WO WO2013053372A1 · 2013 [cited by applicant]
WO WO2013122888A2 · 2013 [cited by applicant]
WO WO2014089365A1 · 2014 [cited by applicant]
WO WO2014107535A1 · 2014 [cited by applicant]
WO WO2014107536A1 · 2014 [cited by applicant]
WO WO2014110442A1 · 2014 [cited by applicant]
WO WO2014151958A1 · 2014 [cited by applicant]
WO WO2015157618A1 · 2015 [cited by applicant]
WO WO2015191907A1 · 2015 [cited by applicant]
WO WO2016100043A1 · 2016 [cited by applicant]
WO WO2018027062A1 · 2018 [cited by applicant]
WO WO2018165048A1 · 2018 [cited by applicant]
WO WO2019226931A1 · 2019 [cited by applicant]
WO WO2020056048A1 · 2020 [cited by applicant]
WO WO2020112542A1 · 2020 [cited by applicant]
Bacterial Infection 101. Available at http://www.onhealth.com/content/l/bacterial_infections (34 pgs) (2017). [cited by applicant]
Bundgaard. Design of Prodrugs. Elsevier. Chapter 1. pp. 1-3 (1985). [cited by applicant]
Burns et al. , Accession No. 2014:955904. STN International CAPLUS database, (Columbus, Ohio) (2014). [cited by applicant]
Burns et al. CAPLUS AN 2014-1130723 (1 pg.) (2014). [cited by applicant]
Byrn et al. Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations. Pharm Res 12(7):945-954 (1995). [cited by applicant]
Cho et al. A practical synthesis of enantiopure 4,4,4-trifluoro-allo-threonine from an easily available fluorinated building block. Tetrahedron Lett. 56:127-131 (2015). [cited by applicant]
Choi et al. Cefiderocol: a novel siderophore cephalosporin. Expert Opin Investig Drugs 27(2):193-197 (2018). [cited by applicant]
Deng et al. Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors. J Med Chem 49:1684-1692 (2006). [cited by applicant]
Eidam et al. Design, synthesis, crystal structures, and antimicrobial activity of sulfonamide boronic acids as β-lactamase inhibitors. J. Med. Chem. 53(21):7852-7863 (2010). [cited by applicant]
Georgiou et al. VNRX-5133, a novel broad-spectrum beta-lactamase inhibitor, enhances the activity of cefepime against resistant Enterobacteriaceae and P. aeruginosa isolates in a neutropenic mouse-thigh infection model.… [cited by applicant]
Germs: Understand and protect against bacteria, viruses and infection, PreventBacterialInfection, 2020. Available at https://www.mayoclinic.org/diseases-conditions/infectious-diseases/in-depth/germs/art-20045289#:-:text… [cited by applicant]
Guillory. Chapter 5: Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids. Polymorphism in Pharmaceutical Solids pp. 183-226 (Brittain, H.G., ed., 1999). [cited by applicant]
Hardy et al. The Chemistry of Some 2-Aminothiazol-4-ylacetic Acid Derivatives and the Synthesis of Derived Penicillins. J Chem Soc Perkin Trans 1:1227-1235 (1984). [cited by applicant]
Higgins et al. In Vitro Activities of the -Lactamase Inhibitors Clavulanic Acid, Sulbactam, and Tazobactam Alone or in Combination with -Lactams against Epidemiologically Characterized Multidrug-Resistant Acinetobacter … [cited by applicant]
ISOMER. https://en.wikipedia.org/wiki/lsomer (5 pgs.) (2015). [cited by applicant]
ISOMER. https://en.wikipedia.org/wiki/Isomer (5 pgs) (2017). [cited by applicant]
Katsube et al. Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment. J Clin Pharmacol 57(5):584-591 (2017). [cited by applicant]
King et al. Molecular Mechanism of Avibactam-Mediated β-Lactamase Inhibition. ACS Infect Dis 1(4):175-84 (2015). [cited by applicant]
Krajnc et al., Bicyclic boronate VNRX-5133 inhibits metallo- and serine-beta-lactamases. Journal of Medicinal Chemistry 62(18):8544-8556 (2019). [cited by applicant]
Martin et al. Rational design and synthesis of a highly effective transition state analog inhibitor of the RTEM-1 β-lactamase. Tetrahedron Lett. 36:8399-8402 (1995). [cited by applicant]
Matteson. Boronic esters in asymmetric synthesis. J Org Chem 78:10009-10023 (2013). [cited by applicant]
Matteson et al. Synthesis of 1-amino-2-phenylethane-1-boronic acid derivatives. Organometallics 3:614-18 (1984). [cited by applicant]
Maxipime (Cefepime Hydrochloride, USP) for Injection) Hospira, Inc. Revised Jun. 2012 (24 pgs). [cited by applicant]
Morandi et al. Structure-based optimization of cephalothin-analogue boronic acids as β-lactamase inhibitors. Bioorg. Med. Chem. 16(3):1195-1205 (2008) (Epub: Nov. 7, 2007). [cited by applicant]
Ness et al. Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 β-lactamase. Biochemistry 39(18):5312-5321 (2000). [cited by applicant]
PCT/US2013/073428 International Search Report and Written Opinion dated Apr. 25, 2014. [cited by applicant]
PCT/US2017/045347 International Search Report and Written Opinion dated Nov. 8, 2017. [cited by applicant]
PCT/US2018/020968 International Search Report and Written Opinion dated Jun. 29, 2018. [cited by applicant]
PCT/US2019/050682 International Search Report and Written Opinion dated Jan. 3, 2020. [cited by applicant]
PCT/US2019/062798 International Search Report and Written Opinion dated Jan. 27, 2020. [cited by applicant]
Powers et al. Structure-based approach for binding site identification on AmpC β-lactamase. J. Med. Chem. 45(15):3222-3234 (2002). [cited by applicant]
Powers et al. Structures of ceftazidime and its transition-state analogue in complex with AmpC β-lactamase: implications for resistance mutations and inhibitor design. Biochemistry 40(31):9207-9214 (2001). [cited by applicant]
Prevent Bacterial Infection. https:/Avww.mayoclinic.org/diseases-conditions/infectious-diseases/in-depth/germs/art-20045289#:-:text=Warding% 200ff%20germs%20and%20infection&text=You%20can%20prevent%20infections%20throug… [cited by applicant]
Reddy et al. Caplus 2014:1118372 (2014) (2 pgs.). [cited by applicant]
Shah et al. Chapter 2: Approaches for Improving Bioavailability of Poorly Soluble Drugs. Pharmaceutical Dosage Forms: Tablets. 3rd edition, vol. 2, chapter 2 (Augsburger et al. editors), p. 62-66 (Dec. 31, 2008). [cited by applicant]
The Chemical Society of Japan (ed.), The Fourth Edition of Lecture Notes in Experimental Chemistry 1: Basic Operations I, pp. 184-189, Published by Maruzen Co., Apr. 5, 1996. [cited by applicant]
U.S. Appl. No. 14/649,527 Office Action dated Nov. 9, 2015. [cited by applicant]
U.S. Appl. No. 15/212,959 Office Action dated Mar. 23, 2017. [cited by applicant]
U.S. Appl. No. 15/797,224 Office Action dated Aug. 13, 2018. [cited by applicant]
U.S. Appl. No. 16/238,363 Office Action dated Sep. 10, 2019. [cited by applicant]
U.S. Appl. No. 16/491,116 Office Action dated Dec. 14, 2020. [cited by applicant]
U.S. Appl. No. 16/491,116 Office Action dated Mar. 25, 2021. [cited by applicant]
U.S. Appl. No. 17/115,514 Office Action dated Apr. 28, 2022. [cited by applicant]
U.S. Appl. No. 17/353,377 Office Action dated Feb. 24, 2023. [cited by applicant]
Weston et al. Structure-based enhancement of boronic acid-based inhibitors of AmpC β-lactamase. J. Med. Chem. 41(23):4577-4586 (1998). [cited by applicant]
Hirayama Yoshinaki. Handbook of organic compound crystal—Principle and know-how, Marzen Co., Ltd., p. 57-84 (Jan. 25, 2008). [cited by applicant]